Therapeutic options and cost considerations in the treatment of ischemic heart disease

Related Experiment Videos

J G Cleland1, A Walker

  • 1University of Glasgow, UK. J.Cleland@biomed.gla.ac.uk

Cardiovascular Drugs and Therapy
|November 4, 1998
PubMed

Insights

Medical treatment is the most cost-effective option for managing ischemic heart disease, especially for patients with well-controlled symptoms. Revascularization surgery offers benefits for intractable symptoms but is less cost-effective overall.

Area of Science:

  • Cardiology
  • Health Economics
  • Clinical Decision-Making

Background:

  • Ischemic heart disease (IHD) presents significant mortality and morbidity challenges.
  • Limited healthcare resources necessitate cost-effective treatment evaluations for IHD.
  • Understanding the economic impact of IHD treatments is crucial for resource allocation.

Purpose of the Study:

  • To compare the costs and benefits of medical treatment versus revascularization for ischemic heart disease.
  • To determine the most cost-effective strategy for managing IHD in a hypothetical patient cohort.
  • To inform clinical decision-making regarding IHD interventions based on economic value.

Main Methods:

  • A hypothetical cohort of 100 patients with ischemic heart disease was modeled.
  • A spreadsheet model was developed using published data to assess costs and outcomes.
  • Key outputs included annual health-service costs and quality-adjusted survival estimates.

Main Results:

  • Medical therapy is the most cost-effective treatment for patients with well-controlled IHD symptoms.
  • Revascularization surgery demonstrates high effectiveness and prognostic benefits for patients with intractable symptoms.
  • Treatment costs below £5,000/QALY are considered highly cost-effective in the UK.

Conclusions:

  • Medical treatment is the preferred cost-effective option for the majority of ischemic heart disease patients.
  • The decision between medical therapy and revascularization should consider symptom severity and cost-effectiveness thresholds.
  • This analysis supports prioritizing medical management for cost-effective ischemic heart disease care.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...